Radionuclide drug conjugates (RDCs) have emerged as transformative agents that integrate diagnosis and therapy into a single ...

The country has reduced the number of children who had never been vaccinated by half, according to The Lancet.

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...

The U.S. childhood immunization schedule, the grid of colored bars pediatricians share with parents, recommends a set of ...

Merck and Daiichi Sankyo acknowledged a "voluntary pause" in the phase III program for the investigational antibody-drug conjugate ifinatamab deruxtecan following a higher-than-expected number of ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

From an investment perspective, Propanc offers a striking contrast to the high-valuation tech stocks now under rotation pressure. With a market capitalization under $15 million, it trades at a ...

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

CDC Deputy Director-General and spokesman Lin Min-cheng (林明誠) on Tuesday said flu activity remained at a relatively low level last week, which is “rare” for this time of the year, although there were ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Daiichi Sankyo begins patient dosing in DESTINY-Endometrial02 phase 3 trial of Enhertu in patients with HER2 expressing endometrial cancer: Tokyo Tuesday, December 23, 2025, 10:00 ...